CAR T-cell and Bispecific Therapies: Clinical Applications and Nursing Management (Participant)

Credit Available: CABRN, ILNA, NP, ASWB

 

Enroll in this Course

FREE

access until December 11, 2025 12:00 am

 

Enroll Now

Activity Description

This recorded webinar is derived from ONS Congress 2024. Earn free CE credit, as you expand your knowledge on the availability and application of CAR T-cell therapy and bispecific therapies to treat patients with hematologic malignancies. Follow a patient from diagnosis, through therapy, and follow-up monitoring while providing input on the patient’s care! Learn about the newest treatments, safety and efficacy, patient management, barriers to access/care, resources for patient education and support from The Leukemia & Lymphoma Society, and more, all to improve patient care!

Time to Complete Activity: 1.50 hours

This course is available from:

June 11, 2024 until December 11, 2025

Course Instructors

Jessica R. Kassay-McAllister, DNP, RN, AGACNP-BC Speaker

Oncology APP Manager, Division of Hematology/Oncology Cellular Therapy/Stem Cell Transplant Program, Effector Cell NP UVA School of Nursing Clinical Faculty, University of Virginia Comprehensive Cancer Center Charlottesville, VA

Krithika Shanmugasundaram, MD Speaker

Assistant Professor of Medicine, Division of Hematology/Oncology Cellular Therapy/Stem Cell Transplant Program University of Virginia Comprehensive Cancer Center Charlottesville, VA

Dan T. Vogl, MD, MSCE Speaker

Director, Abramson Cancer Center Clinical Research Unit, Associate Professor of Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia, PA

Target Audience

Oncology nurses, nurse practitioners, and social workers involved in the care of patients with hematologic malignancies.

Course content level for social workers: all levels

Educational Objectives
After completing this activity, the participant should be better able to:

• • Describe the role of CAR T- cell therapy and bispecifics in treating blood cancer
  • Apply knowledge of communication strategies, streamlined patient assessment, disparities in care, and strategies for multidisciplinary teams to improve patient-centered care
  • Explain data surrounding CAR T-cell and bispecific therapies including their proper application, efficacy, and adverse events, and resources to support patients and their caregivers
  • Optimize patient assessment to ensure effective, individualized patient care including implementation of bridging therapy when indicated 
  • Utilize appropriate tools to properly assess risk for progression and response to cellular therapies

Accreditation, Support and Credit

Nursing Continuing Professional Development

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.

Social Worker Continuing Education

The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credits.

The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.

Nurse Practitioner Continuing Education

This activity is approved for 1.5 contact hour(s) of continuing education (which includes 0.35 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24066677. This activity was planned in accordance with AANP Accreditation Standards and Policies.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (ONC, CBCN, CPHON, AOCNP), Oncology Nursing Practice (ONC), Professional Practice/Performance (BMTCN, AOCNP), Psychosocial Dimensions of Care (AOCNP, CPHON, ONC, CBCN), Symptom Management, Palliative Care, Supportive Care (ONC, CPHON, AOCNP), Treatment (OCN, CBCN, AOCNP, CPHON). Total points: 1.5*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Support Statement

This activity is supported in part by an educational grant from Bristol Myers Squibb. Additional funding provided by The Leukemia & Lymphoma Society.

Providers

This activity is provided by The Leukemia & Lymphoma Society.

Disclosure of Conflicts of Interest Policy

All persons who may impact the content of a CE activity, including faculty and planners, are required to fully disclose current and recent financial relationships with commercial interests. A conflict of interest may be considered to exist if such a person has financial relationships with the grantor or any non-eligible entities (commercial interests) that may have a direct impact on the content of the program. Financial relationship is defined as being a shareholder, consultant, grant recipient, research participant, employee, and/or recipient of other financial or material support. Recent is defined as within the past 24 months. The participants in this CE activity must be made aware of any such financial relationship(s). This disclosure policy is intended to protect all parties involved from any potential conflict of interest that may arise.

Faculty Disclosures

Jessica R. Kassay-McAllister DNP, RN, AGACNP-BC, has no financial relationships with ineligible companies.

Krithika Shanmugasundaram, MD, has no financial relationships with ineligible companies.

Dan T. Vogl, MD, MSCE, has financial relationships with the following companies:
Advisory Board/Consultant: AbbVie, CSL Behring, Genentech, Takeda
Research/Grant: Active Biotech, Takeda

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. 

If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@mlieducation.org.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.